PL-02 risk assessment for cancer-associated thrombosis: What is the best approach?

Thrombosis Research

Volumn 129, Issue SUPPL. 1, 2012, Pages

  Khorana, Alok A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cancer; Prevention; Risk factors; Venous thromboembolism

Indexed keywords

D DIMER; HEMOGLOBIN; THROMBOPLASTIN; TUMOR MARKER;

ANTIANGIOGENIC THERAPY; ANTICOAGULANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; NEOPLASM; OUTPATIENT CARE; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM; COMORBIDITY; EPIDEMIOLOGY; MORTALITY; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL; SURVIVAL RATE; THROMBOSIS;

CAUSALITY; COMORBIDITY; HUMANS; NEOPLASMS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; THROMBOSIS;

EID: 84862115634     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(12)70009-9     Document Type: Conference Paper

References (54)

1. JA Heit, WM O'Fallon, TM Petterson, CM Lohse, MD Silverstein, DN Mohr et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study Arch Intern Med 162 2002 1245 1248 (Pubitemid 34595030)
2. AA Khorana, CW Francis, E Culakova, NM Kuderer, GH Lyman Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients Cancer 110 2007 2339 2346 (Pubitemid 350100757)
3. AA Khorana, GC Connolly Assessing risk of venous thromboembolism in the patient with cancer J Clin Oncol 27 2009 4839 4847
4. JW Blom, CJ Doggen, S Osanto Rosendaal FR Malignancies, prothrombotic mutations, and the risk of venous thrombosis Jama 293 2005 715 722 (Pubitemid 40216041)
5. CW Francis Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients N Engl J Med 356 2007 1438 1444 (Pubitemid 46562358)
6. A Maraveyas, J Waters, R Roy, D Fyfe, D Propper, F Lofts et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer Eur J Cancer 2011
7. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 106:371-8.
8. CL O'Connell, WD Boswell, V Duddalwar, A Caton, LS Mark, C Vigen et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance J Clin Oncol 24 2006 4928 4932 (Pubitemid 46630922)
9. M Mandala, S Barni, I Floriani, L Isa, G Fornarini, M Marangolo et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the "GISCAD-alternating schedule" study findings Eur J Cancer 45 2009 65 73
10. MW Reynolds, A Shibata, S Zhao, N Jones, K Fahrbach, LT Goodnough Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysis Curr Med Res Opin 24 2008 497 505 (Pubitemid 351294399)
11. AA Khorana, RL Fine Pancreatic cancer and thromboembolic disease Lancet Oncol 5 2004 655 663 (Pubitemid 40267849)
12. HK Chew, AM Davies, T Wun, D Harvey, H Zhou, RH White The incidence of venous thromboembolism among patients with primary lung cancer J Thromb Haemost 6 2008 601 608 (Pubitemid 351404927)
13. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with Cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29:3466-73.
14. AA Khorana, NM Kuderer, E Culakova, GH Lyman, CW Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902 4907
15. J Murray Myeloproliferative disorders Clin Med 5 2005 328 332 (Pubitemid 41176210)
16. AA Khorana, CW Francis, E Culakova, RI Fisher, NM Kuderer, GH Lyman Thromboembolism in hospitalized neutropenic cancer patients J Clin Oncol 24 2006 484 490 (Pubitemid 46630468)
17. MM Samama An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study Arch Intern Med 160 2000 3415 3420
18. JA Heit, MD Silverstein, DN Mohr, TM Petterson, WM O'Fallon, LJ Melton 3rd Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 2000 809 815 (Pubitemid 30165241)
19. JW Blom, JP Vanderschoot, MJ Oostindier, S Osanto, FJ van der Meer, FR Rosendaal Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study J Thromb Haemost 4 2006 529 535
20. N Starling, S Rao, D Cunningham, T Iveson, M Nicolson, F Coxon et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group J Clin Oncol 27 2009 3786 3793
21. FA Scappaticci, JR Skillings, SN Holden, HP Gerber, K Miller, F Kabbinavar et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239 (Pubitemid 47299901)
22. SR Nalluri, D Chu, R Keresztes, X Zhu, S Wu Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
23. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28:2280-5.
24. EA Akl, G Karmath, V Yosuico, SY Kim, M Barba, F Sperati et al. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters Cochrane Database Syst Rev 2007 CD006468.
25. CL Bennett, SM Silver, B Djulbegovic, AT Samaras, CA Blau, KJ Gleason et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia JAMA 299 2008 914 924 (Pubitemid 351397066)
26. G Agnelli, G Bolis, L Capussotti, RM Scarpa, F Tonelli, E Bonizzoni et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the RISTOS project Ann Surg 243 2006 89 95 (Pubitemid 43054059)
27. K Kroger, D Weiland, C Ose, N Neumann, S Weiss, C Hirsch et al. Risk factors for venous thromboembolic events in cancer patients Ann Oncol 17 2006 297 303 (Pubitemid 43160121)
28. AA Khorana, CW Francis, E Culakova, GH Lyman Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study Cancer 104 2005 2822 2829 (Pubitemid 41798294)
29. R Simanek, R Vormittag, C Ay, G Alguel, D Dunkler, I Schwarzinger et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) J Thromb Haemost 8 2010 114 120
30. GC Connolly, AA Khorana, NM Kuderer, E Culakova, CW Francis, GH Lyman Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy Thromb Res 126 2010 113 118
31. MT Stender, JB Frokjaer, TB Larsen, S Lundbye-Christensen, O Thorlacius-Ussing Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up Dis Colon Rectum 52 2009 446 451
32. C Ay, R Vormittag, D Dunkler, R Simanek, AL Chiriac, J Drach et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study J Clin Oncol 27 2009 4124 4129
33. RS Kasthuri, MB Taubman, N Mackman Role of tissue factor in cancer J Clin Oncol 27 2009 4834 4838
34. JI Zwicker, HA Liebman, D Neuberg, R Lacroix, KA Bauer, BC Furie et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy Clin Cancer Res 15 2009 6830 6840
35. AA Khorana, SA Ahrendt, CK Ryan, CW Francis, RH Hruban, YC Hu et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer Clin Cancer Res 13 2007 2870 2875 (Pubitemid 46849560)
36. LY Han, CN Landen Jr., AA Kamat, A Lopez, DP Bender, P Mueller et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma J Clin Oncol 24 2006 755 761 (Pubitemid 46622042)
37. AA Khorana, CW Francis, KE Menzies, JG Wang, O Hyrien, J Hathcock et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer J Thromb Haemost 6 2008 1983 1985
38. J Thaler, C Ay, H Weinstabl, D Dunkler, R Simanek, R Vormittag et al. Circulating procoagulant microparticles in cancer patients Ann Hematol 90 4 2011 447 453
39. C Ay, N Mackman, NS Key, A Kaider, J Thaler, C Marosi et al. Microparticle-associated tissue factor activity and occurrence of venous thromboembolism in brain, gastrointestinal and pancreatic cancer J Thromb Haemost 2011 O-MO-133.
40. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood 116:5377-82.
41. M Mandala, M Clerici, I Corradino, C Vitalini, S Colombini, V Torri et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the "SENDO experience" Ann Oncol 2011
42. A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, B Barlogie et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2008 414 423 (Pubitemid 351255436)
43. MM Samama, AT Cohen, J-Y Darmon, L Desjardins, A Eldor, C Janbon et al. A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely ILL Medical Patients N Engl J Med 341 11 1999 793 800 (Pubitemid 29420474)
44. A Leizorovicz, AT Cohen, AG Turpie, CG Olsson, PT Vaitkus, SZ Goldhaber Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 110 2004 874 879 (Pubitemid 39096017)
45. AT Cohen, BL Davidson, AS Gallus, MR Lassen, MH Prins, W Tomkowski et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial BMJ 332 2006 325 329
46. GH Lyman, AA Khorana, A Falanga, D Clarke-Pearson, C Flowers, M Jahanzeb et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer J Clin Oncol 2007
47. LD Wagman, MF Baird, CL Bennett, PL Bockenstedt, SR Cataland, J Fanikos et al. Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology J Natl Compr Canc Netw 6 2008 716 753
48. G Agnelli, G Gussoni, C Bianchini, M Verso, M Mandala, L Cavanna et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Lancet Oncol 10 2009 943 949
49. G Agnelli, DJ George, W Fisher, AK Kakkar, MR Lassen, P Mismetti, P Mouret, U Chaudhari, AG Turpie The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study J Clin Oncol, 2011. ASCO Annual Meeting 29 2011 Abstract No. LBA9014.
50. UP Riess, G. Deutschinoff, B. Opitz, M. Stauch, P. Reitzig, S. Hahnfeld, A. Hilbig, J. Stieler, H. Oettle A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial J Clin Oncol 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27.
51. George D, Agnelli G, Fisher W, AK K, Lassen MR, Mismetti P, et al. Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO. Blood: Proceedings of Annual Meeting of American Society of Hematology 2011. 2011;Abstract 206.
52. JC Kearney, S Rossi, K Glinert, D Henry Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: a retrospective chart validation of a VTE prediction model Blood 2009 Abstract 2503.
53. Price LH, Nguyen MB, Picozzi VJ, Kozarek RA. Portal vein thrombosis in pancreatic cancer: natural history, risk factors and implications for patient management. 2010 Gastrointestinal Cancer Symposium Program and Proceedings 2010;Abstract 143.
54. AA Khorana, K Herman, D Rubens, CW Francis A Predictive Risk Score for Cancer-Associated Thrombosis: Role of Screening in A Prospective Study Blood 2010 Abstract 3173.